Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

PRVB


Top 10 Correlated ETFs

PRVB


Top 10 Correlated Stocks

PRVB


In the News

10:53 03 Oct 2022 PRVB

1 Green Flag and 1 Red Flag for Provention Bio

It could be a make-or-break end of the year for the company.

04:01 03 Oct 2022 PRVB

Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

RED BANK, N.J. , Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C.

10:53 03 Oct 2022 PRVB

2 Under-the-Radar Biotech Stocks to Buy in 2022

It's been a wild 12 months for these companies.

01:32 03 Oct 2022 PRVB

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript

Provention Bio, Inc. (NASDAQ:PRVB ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche - Chief Financial Officer Ashleigh Palmer - Co-Founder, President, Chief Executive Officer Jason Hoitt - Chief Commercial Officer Francisco Leon - Co-Founder & Chief Scientific Officer Conference Call Participants Justin Kim - Oppenheimer Raghuram Selvaraju - H.C. Wainwright Prakhar Agrawal - Cantor Fitzgerald Thomas Smith - SVB Securities David Hoang - SMBC Nikko Operator Good morning.

12:02 03 Oct 2022 PRVB

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

07:30 03 Oct 2022 PRVB

Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

RED BANK, N.J. , July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022, before the opening of the U.S. financial markets.

10:07 03 Oct 2022 PRVB

This Stock Could Soar by Nearly 300%, Says Wall Street

Are the Street's predictions too optimistic?

07:30 03 Oct 2022 PRVB

Provention Bio to Present at the Jefferies Global Healthcare Conference

RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8 th 2022 at 9:00 am EST in New York City.

11:23 03 Oct 2022 PRVB

2 High-Risk, High-Reward Stocks for Contrarian Investors

Feeling adventurous?

12:11 03 Oct 2022 PRVB

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2022 Results - Earnings Call Transcript

Provention Bio, Inc. (NASDAQ:PRVB ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ashleigh Palmer – Co-Founder, President, Chief Executive Officer Francisco Leon – Co-Founder & Chief Scientific Officer Thierry Chauche – Chief Financial Officer Jason Hoitt – Chief Commercial Officer Robert Doody – Vice President, Investor Relations Conference Call Participants Gregory Renza – RBC Capital Markets Thomas Smith – SVB Leerink David Hoang – SMBC Nikko Securities America, Inc Operator Good morning. My name is Kate, and I will be your conference Operator today.

Financial details

Company Rating
Neutral
Market Cap
366.97M
Income
-104.51M
Revenue
2.72M
Book val./share
1.22
Cash/share
1.31
Dividend
-
Dividend %
-
Employees
82
Optionable
No
Shortable
Yes
Earnings
02 Nov 2022
P/E
-2.79
Forward P/E
-1.83
PEG
2.28
P/S
107.03
P/B
3.7
P/C
3.47
P/FCF
-3.15
Quick Ratio
3.36
Current Ratio
3.59
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-1.65
EPS next Y
-2.48
EPS next Q
-0.62
EPS this Y
-3.72%
EPS next Y
50%
EPS next 5Y
50%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
28.62%
EPS Q/Q
31.43%
-
-
-
-
SMA20
-20%
SMA50
-
SMA100
-
Inst Own
39.59%
Inst Trans
1.3%
ROA
-100%
ROE
-100%
ROC
-1.41%
Gross Margin
27%
Oper. Margin
-4111%
Profit Margin
-3841%
Payout
-
Shs Outstand
81.55M
Shs Float
51.3M
-
-
-
-
Target Price
-
52W Range
3.185-8.04
52W High
-43.19%
52W Low
+51.5%
RSI
49
Rel Volume
0.48
Avg Volume
772.56K
Volume
369.42K
Perf Week
2.83%
Perf Month
-7.06%
Perf Quarter
-29.32%
Perf Half Y
-37.74%
-
-
-
-
Beta
2.3632
-
-
Volatility
0.18%, 0.34%
Prev Close
1%
Price
4.545
Change
3.3%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000.02
Net income per share
-1.18-1.06-1.88-1.81
Operating cash flow per share
-1.01-0.89-1.46-1.51
Free cash flow per share
-1.01-0.89-1.48-1.53
Cash per share
2.612.12.321.51
Book value per share
2.662.022.121.75
Tangible book value per share
2.662.022.121.75
Share holders equity per share
2.662.022.121.75
Interest debt per share
000.010.01
Market cap
51.35M645.03M722.33M262.5M
Enterprise value
-7.19M605.86M620.75M184.9M
P/E ratio
-1.94-14.9-7.33-2.29
Price to sales ratio
000188.17
POCF ratio
-2.27-17.89-9.46-2.75
PFCF ratio
-2.27-17.89-9.33-2.72
P/B Ratio
0.867.856.52.37
PTB ratio
0.867.856.52.37
EV to sales
000132.54
Enterprise value over EBITDA
0.27-13.65-6.23-1.61
EV to operating cash flow
0.32-16.8-8.13-1.94
EV to free cash flow
0.32-16.8-8.02-1.92
Earnings yield
-0.52-0.07-0.14-0.44
Free cash flow yield
-0.44-0.06-0.11-0.37
Debt to equity
000.010.01
Debt to assets
0.030.040.140.18
Net debt to EBITDA
2.230.881.020.67
Current ratio
32.8922.397.564.44
Interest coverage
0000
Income quality
0.860.830.770.83
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
00033.94
Research and developement to revenue
00049.91
Intangibles to total assets
0000
Capex to operating cash flow
000.010.01
Capex to revenue
000-0.69
Capex to depreciation
00-33.67-2.48
Stock based compensation to revenue
0008.49
Graham number
8.46.949.468.46
ROIC
-0.45-0.54-0.89-1.02
Return on tangible assets
-0.43-0.5-0.77-0.84
Graham Net
2.5321.991.11
Working capital
59.66M82.16M109.82M78.31M
Tangible asset value
0000
Net current asset value
59.66M82.16M109.11M76.21M
Invested capital
000.010.01
Average receivables
0000
Average payables
4.07M4.67M7.57M5.56M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.44-0.53-0.89-1.03
Capex per share
00-0.02-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00.010.010.010.01
Net income per share
-0.46-0.43-0.41-0.35-0.46
Operating cash flow per share
-0.47-0.4-0.37-0.24-0.44
Free cash flow per share
-0.49-0.4-0.37-0.24-0.44
Cash per share
2.782.381.51.341.31
Book value per share
2.492.121.751.491.22
Tangible book value per share
2.492.121.751.491.22
Share holders equity per share
2.492.121.751.491.22
Interest debt per share
0.010.010.010.010.01
Market cap
534.25M405.6M356.17M464.09M258.86M
Enterprise value
383.13M266.88M278.57M389.73M201.5M
P/E ratio
-4.58-3.75-3.45-5.28-2.18
Price to sales ratio
0598.23496.75800.15347
POCF ratio
-17.75-16-15.18-30.88-9.1
PFCF ratio
-17.36-16.01-15.16-30.88-9.03
P/B Ratio
3.383.023.224.933.29
PTB ratio
3.383.023.224.933.29
EV to sales
0393.63388.52671.95270.11
Enterprise value over EBITDA
-12.73-9.91-10.84-13.52-6.85
EV to operating cash flow
-12.73-10.53-11.88-25.93-7.09
EV to free cash flow
-12.45-10.53-11.85-25.93-7.03
Earnings yield
-0.05-0.07-0.07-0.05-0.11
Free cash flow yield
-0.06-0.06-0.07-0.03-0.11
Debt to equity
000.010.010.01
Debt to assets
0.140.150.180.230.25
Net debt to EBITDA
5.025.153.022.581.95
Current ratio
7.337.464.443.393.59
Interest coverage
000-510.19-204.34
Income quality
1.030.940.910.680.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
014.7915.821.2218.77
Research and developement to revenue
026.1421.2729.9222.22
Intangibles to total assets
00000
Capex to operating cash flow
0.020000.01
Capex to revenue
00-0.060-0.3
Capex to depreciation
-8.330-0.310-1.66
Stock based compensation to revenue
04.623.615.724.29
Graham number
5.084.5143.43.54
ROIC
-0.19-0.2-0.23-0.3-0.38
Return on tangible assets
-0.16-0.17-0.19-0.18-0.28
Graham Net
2.3821.110.90.91
Working capital
155.95M134.46M78.31M64.74M65.15M
Tangible asset value
00000
Net current asset value
155.3M131.5M76.21M63.53M64.63M
Invested capital
000.010.010.01
Average receivables
00000
Average payables
5.55M5.44M5.39M7.24M6.45M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.18-0.2-0.23-0.23-0.38
Capex per share
-0.010000

Frequently Asked Questions

What is Provention Bio, Inc. stock symbol ?

Provention Bio, Inc. is a US stock , located in Oldwick of New jersey and trading under the symbol PRVB

What is Provention Bio, Inc. stock quote today ?

Provention Bio, Inc. stock price is $4.545 today.

Is Provention Bio, Inc. stock public?

Yes, Provention Bio, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap